Clinical Trial

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Protocol Amendment History 40 amendments
This ClinicalTrials.gov record has been amended 40 times since 2022-08-04; most recent amendment 2026-06-19.
Status change: Recruiting → Active, Not Recruiting 2025-11-26
Status change: Active, Not Recruiting → Recruiting 2024-09-13
Status change: Recruiting → Active, Not Recruiting 2023-05-24
Status change: Not Yet Recruiting → Recruiting 2022-09-23
Trial Details
NCT Number NCT05490446
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Myelodysplastic Syndromes
Enrollment 87 participants
Start Date 2022-11-07
Primary Completion 2026-03-17 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-30